Sign up to access all our data and the evidence and analysis underlying our overall scores. Once you've created an account, we'll get in touch with further details:
Sign Up
| Overall Assessment |
Comment |
Score |
| Moderate |
Dr. Reddy’s Laboratories offers a moderate level of transparency on its climate-related lobbying. It identifies concrete policies it engages on, most notably the Bureau of Energy Efficiency’s “Perform Achieve and Trade (PAT) scheme” and the development of “guidelines on HVACs to maintain temperature for thermal comfort,” and explains that it supports extending the PAT scheme to cover the pharmaceutical sector. The company also clarifies how it tries to influence these measures, describing direct “consultations” with the Bureau of Energy Efficiency and indirect advocacy through trade associations such as the Confederation of Indian Industries and participation in the India CEO Forum on Climate Change. Finally, it states the concrete outcomes it seeks—expanding the PAT scheme to its sector and establishing HVAC efficiency guidelines—while confirming that these positions are “Support with no exceptions” and aligned with the Paris Agreement. Although the disclosures occasionally note zero reported lobbying expenditure, the narrative still provides named policies, methods and targets, and specific aims, giving stakeholders a reasonable understanding of the company’s climate-policy advocacy.
|
2
|
| Overall Assessment |
Comment |
Score |
| Limited |
Dr Reddy’s Labs provides only limited insight into how it governs its advocacy activities. The company states that it “performs the function of policy advocacy in a transparent and responsible manner while engaging with all the authorities” and insists that “policy advocacy must preserve and expand the public good and thus, it does not advocate any policy change to benefit itself or a select few,” which signals an intention to align its lobbying with a broad public-interest principle. It also discloses that senior leaders hold influential positions in bodies such as the Indian Pharmaceutical Alliance and the CII National Committee on Pharmaceuticals, demonstrating awareness of its indirect lobbying channels. However, we found no evidence of a formal process that monitors or reviews whether either direct or trade-association lobbying is consistent with the company’s climate or broader sustainability goals, nor any mention of board or senior-management oversight, dedicated committees, or periodic assessments of lobbying alignment. Consequently, the disclosure suggests an ethical aspiration but not a clearly defined governance framework for lobbying alignment, particularly on climate-related issues.
|
1
|